Blechum pyramidatum (Lam.) Urb. is a species of extensive medicinal use in the American continent. In fact, antidiabetic and anticancer preparations from this plant have been patented in Mexico, even though their active constituents are not yet known. It was recently discovered that B. pyramidatum inhibits the action of the -glucosidase enzyme, thereby corroborating the antidiabetic properties attributed to this plant. The primary purpose of this study was to identify and characterize the -glucosidase inhibitors from this species. Bioassay-guided fractionation of a crude extract of B. pyramidatum led to the isolation of a main -glucosidase inhibitor, Palmitic acid (IC 50 237.5). This compound was identified by both spectroscopic and spectrometric analysis. Its inhibitory activity was similar to that of the antidiabetic drug acarbose (IC 50 241.6 µM), which was used as a positive control in our bioassay. Kinetic analysis established that palmitic acid acted as a competitive inhibitor. Docking analysis predicted that this compound binds to the same site as acarbose does in the human intestinal α-glucosidase (PDB: 3TOP). The presence of palmitic acid in B. pyramidatum and its potent inhibitory activity against α-glucosidase enzyme provides solid evidence to support the antidiabetic use of this plant in traditional medicine.
Medicinal plants have been systematically used since ancient times, especially in countries where significant ancestral cultures flourished [1] . Despite today's technological advances, medicinal plants continue to be a widely used resource to prevent and treat human diseases. Recently, the World Health Organization estimated that approximately three-quarters of the world's population trust and utilize plants for their health care needs [2] . Faced with this panorama, scientists from all over the world must continue to generate better information to develop recommendations for effective and safe uses of many medicinal plants.
Blechum pyramidatum (Lam.) Urb. is a species of wide medicinal use in different countries of the American continent. Cooking of the leaves is prescribed to treat skin problems [3] . A decoction of this plant can be administered as a diuretic [4] and as an antiemetic [5] . In some places, this plant is applied to treat snakebites [6] . In Mexico, the antidiabetic and anticancer uses of this plant have been patented, although the active compounds have never been isolated nor identified [7] . Therefore, there is an urgent need to identify the active components of this plant to guarantee its quality and safe use. In a preliminary study, we detected that the organic extract from this plant showed significant inhibitory activity against the α-glucosidase enzyme, although it was not possible for us to fully identify the component(s) responsible for that activity [8] . The latter was partly due to the presence of large amounts of chlorophyll and other related compounds, which interfered with the bioactivity results we obtained in the initial extraction of this plant. Still, obtained results suggests that inhibition of -glucosidase enzyme is part of antidiabetic mechanisms from this plant.
It is important to point out that conventional bioassays performed to detect -glucosidase activity typically quantify the enzymatic activity by measuring the absorbance of the reaction mixture at 400 nm [9a-c] . Chlorophyll and related compounds also exhibit intense absorption peaks at this same wavelength. Therefore, the removal of these types of compounds prior to chemical studies is essential to obtain more accurate results in detecting -glucosidase bioactivity. For this reason, we proceeded with the removal of chlorophyll and related compounds from the initial crude extract by using activated carbon to avoid interferences in the enzymatic readings.
The aerial parts of B. pyramidatum were macerated with a mixture of CHCl 3 -MeOH (1:1). Subsequently, this mixture was blended with activated carbon, which was filtered and concentrated to obtain the crude extract. This extract inhibited 69.4 % of the -glucosidase activity at a final concentration of 6.25 mg/mL. Afterward, the organic extract was dissolved in a hydro-methanol mixture (20:80) and successively partitioned by two solvents, hexane and ethyl acetate, to obtain three major fractions with increasing polarity. Of these three fractions, only the hexane fraction showed promising activity (80.1 % of enzyme inhibition at 6.25 mg/mL). Bioassayguided fractionation of the hexane fraction allowed the isolation of palmitic acid (compound 1), as the main active compound from B. pyramidatum. This compound was identified by spectroscopic analyses including ESI-HR-MS and NMR ( 1 H, 13 C, DEPT 135, DEPT 90, COSY, NOESY, HMBC and HMQC) [8, 10] .
Compound 1 inhibited the α-glucosidase enzyme in a concentrationdependent manner with an IC 50 value of 237.5 µM therefore showing similar potency to acarbose (positive control, IC 50 241.6 µM). During -glucosidase evaluations, we initially found that palmitic acid only showed moderate activity, which did not correlate with the activity detected in the hexane fraction through which this compound was isolated. This fact allowed us to recognize that palmitic acid had poor solubility in DMSO. There have been previous reports about -glucosidase inhibition by fatty acids, including palmitic and oleic acids, with DMSO being regularly used to solubilize samples as part of standard protocols to detect bioactivity [11a-c] . Our evidence suggested that a reevaluation of the inhibition of the α-glucosidase enzyme by palmitic acid in other solvents was necessary to both determine whether there was an effect by the reduced solubility of palmitic acid in DMSO and to compare our findings to previously reported enzymatic activity. To find a solvent which would allow us to get more reliable results for palmitic acid activity -and, in general, for low polar compounds -we proceeded to evaluate the inhibition of -glucosidase by some common solvents in different quantities, including ethanol, methanol, propanol, and isopropanol. Through these tests, we detected that ethanol in small volumes only slightly decreased the α-glucosidase activity and that palmitic acid was solubilized better than with DMSO.This finding allowed us to obtain more real inhibition results for low polarity compounds.
We proceeded to evaluate the activity of palmitic acid using ethanol to compare to the results we obtained with DMSO. We also assessed oleic acid since this compound has similar solubility properties to those of palmitic acid, and we also re-evaluated the positive control, acarbose (IC 50 217.7 µM in DMSO). As a result, oleic acid showed potent α-glucosidase inhibitory activity (IC 50 38.9 µM), even better than palmitic acid, and acarbose showed similar potency to that displayed using DMSO (IC 50 241.6 µM in ethanol). This evidence suggests that reported data about -glucosidase inhibition by certain low polar compounds could be inaccurate due to their poor solubility DMSO which is used in most standard protocols.
To obtain further evidence of the nature of the interaction of palmitic (1) and oleic acids (2) with α-glucosidase, we carried out kinetic analyses. Lineweaver-Burk plots [12a] were constructed using different concentrations of substrate and fatty acids 1-2 ( Figure 1) . The results in Figure 2 and Figure 3 indicated that compounds 1-2 showed typical reversible competitive plots, with series of lines having the same y-intercept as the enzyme without inhibitors. These results suggested that compounds 1-2 bind to α-glucosidase or to the substrate-enzyme complex. Acarbose also behaved as a competitive inhibitor [12a] . These results show that both fatty acids are potent competitive inhibitors of the α-glucosidase enzyme. Taking into consideration the results of the kinetic analysis performed, we conducted a molecular docking study to evaluate the putative binding mode of fatty acids 1-2 into the human intestinal α-glucosidase (PDB: 3TOP). Results indicate that fatty acids bind mainly through hydrophobic interactions. Figure 4 shows the superposition of docking poses of compounds 1-2 and acarbose in the binding site. It is interesting to note that despite the analyzed fatty acids being mainly hydrophobic they bind to the same site as acarbose, which is a more polar compound compared to fatty acids 1-2. As expected, acarbose interacts with the binding site through many hydrogen bonds (Figure 5a ) and compounds 1-2 interact mainly via hydrophobic interactions (Figure 5b ). However, palmitic acid interacts with Asp 1526 and Arg 1582 through the formation of hydrogen bonds while oleic acid weakly interacts with Lys 1460 by the formation of hydrogen bonds with hydroxyl groups (Figures 6). Finally, in the results of the docking analysis, it is clearly observed that the oleic acid pose fits better than the palmitic acid pose in the -glucosidase receptor site. This finding suggests that the threedimensional arrangement due to the presence of the double bond is responsible for the better activity displayed by oleic acid.
In summary, palmitic acid was isolated from the B. pyramidatum active fraction against -glucosidase. Even though this compound was previously reported as a weak inhibitor of -glucosidase, our data suggests that the use of a polar solvent (DMSO) in the bioassay conditions has produced inaccurate results, especially for low polarity compounds. Oleic acid showed higher activity than both palmitic acid and acarbose. These compounds exhibited a competitive type of inhibition against S. cerevisiae α-glucosidase. Therefore, this fatty acid-rich plant might also be an interesting alternative for reducing blood sugar level in people affected by DM. 
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Experimental
General Experimental Procedures: NMR spectra were acquired on Jeol Eclipse 400 MHz spectrometer (referenced to  H 7.26,  C 77.0 for CDCl 3 ). APCIHR-MS were acquired on a JEOL LC-mate mass spectrometer. The purification of the compounds was carried out on Agilent 1100 HPLC system equipped with a quaternary pump, a diode array detector, and a normal phase silica gel column (Phenomenex Luna, 4.6 mm × 100 mm, 5 μm) at a flow rate of 1 mL/min. Column chromatography was used with silica gel 60 (70-230 mesh, Merck). TLC (analytical) was performed on pre-coated silica gel 60 F254 plates (Merck). All solvents were HPLC grade and used without further purification.
Plant material and extract preparation: B. pyramidatum (Acanthaceae) was collected in Santa Clara, Chiriquí, in the Republic of Panama. This plant was identified by Jorge Lezcano and was deposited to the Herbarium at the University of Panama. The aerial plant parts were dried at room temperature for a week and then were grounded for further study. This material (50.0 g) was extracted by maceration at room temperature with a mixture of CHCl 3 -MeOH (1:1). The solvent mixture was mixed with activated carbon (charcoal; 5 g) and stirred for 20 minutes at room temperature. The solution was filtered through celite in a Büchner funnel. The resulting solution was evaporated under reduced pressure to remove the solvent to leave a semi-solid paste (4.6 g).
Chemical studies: The crude extract was subjected to bioassayguided fractionation in which the extract was re-suspended in a mixture of water-MeOH 70:30 and sequential partitions were made with Hexanes [Hex] (5×200 mL) and ethyl acetate [AcoEt] (5×200 mL). Each obtained fraction, including the final hydromethanol fraction, was evaporated to dryness and then subjected to enzymatic assay. Hex fraction (active, 1.61 g) was fractionated by column chromatography on silica gel (35 g). The column was eluted with Hex, followed by a gradient of Hex:EtOAc (1:0→0:1) and finally with a gradient of EtOAc:MeOH (1:0→1:1). Altogether, 109 fractions (25 ml each) were collected and combined according to their TLC profiles to yield nine primary fractions (FA to FI), which were re-evaluated against -glucosidase and the activity was presented in fraction FA [eluted with 100% Hex]. Fraction FA (0.31 g) was further subjected to silica gel column chromatography and eluted with a gradient of Hex:EtOAc (1:0→0:1). This process led to six fractions (FA-1 to FA-6), which were also evaluated. Fraction FA-2 was eluted with Hex:EtOAc (9:1) to afford 3.1 mg of compound 1, which was the compound responsible for the activity. The other fractions were also evaluated but did not show an inhibitory effect in vitro against the enzyme -glucosidase.
Alpha-glucosidase inhibitory assay:
The -glucosidase inhibitory assay was performed according to Chan and collaborators [9a] , with modifications [12a and b]. α-Glucosidase from baker's yeast was purchased from Sigma Chemical Co. The inhibition was measured spectrophotometrically at pH 7.0 and 37°C employing 2 mM pnitrophenyl α-D-glucopyranoside (PNP-G) as a substrate and 32 mU/mL of the enzyme, in 100 mM potassium phosphate buffer (enzyme stock). Acarbose was dissolved in phosphate buffer, and serial dilutions were prepared (in order to obtain the IC 50 ) and employed as positive control. The absorbance (A) of 4-nitrophenol released by the hydrolysis of PNP-G was measured at 400 nm by Synergy HT Bio Tek microplate spectrophotometer. A 20 µL of acarbose, plant extract or isolated compound solution (in DMSO or Etanol) were incubated for 7 min with 150 µL of enzyme stock at 37°C. After incubating, 150 µL of substrate was added and further incubated for 20 min at 37°C. All assays were performed in 96-well microplates (Greiner bio-one 655101) in triplicate. The activity of samples was calculated as a percentage in comparison to a control according to the following equation: (b) (a)
